745770-80-3

Basic information

• Product Name: Benzamide, 4-(1-amino-1-methylethyl)-N-4-pyridinyl- (9CI)
• Synonyms: Benzamide, 4-(1-amino-1-methylethyl)-N-4-pyridinyl- (9CI)
• CAS NO: 745770-80-3
• Molecular Formula: C15H17N3O
• Molecular Weight: 255.31498
• Product Categories: AMIDE
• Mol File: 745770-80-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzamide, 4-(1-amino-1-methylethyl)-N-4-pyridinyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 4-(1-amino-1-methylethyl)-N-4-pyridinyl- (9CI)(745770-80-3)
• EPA Substance Registry System: Benzamide, 4-(1-amino-1-methylethyl)-N-4-pyridinyl- (9CI)(745770-80-3)

Safety Data

• Hazardous Substances Data: 745770-80-3(Hazardous Substances Data)

Relevant articles and documents

VISUAL FUNCTION DISORDER IMPROVING AGENTS

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo?2,3-büpyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent

Preventives/remedies for kidney diseases

A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS

An agent for the prophylaxis and treatment of vascular constriction is provided, which contains a compound having a Rho kinase inhibitory activity. In particular, a compound having a Rho kinase inhibitory activity, for example, (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, suppresses regenerative intima proliferation after disorder of blood vessel and has various other actions. Therefore, it is useful as an agent for the prophylaxis and treatment of vascular constriction, specifically, an agent for the prophylaxis and treatment of vascular constriction induced by disorder of vascular wall, such as vascular restenosis that occurs after an operation of percutaneus transluminal coronary angioplasty, vascular restenosis that occurs after an operation of percutaneus transluminal angioplasty, vascular constriction that occurs after vascular reconstruction, such as DCA, operation of intravascular indwelling of stent and the like, and vascular constriction that occurs after organ transplantation.